MHC class I alleles and their exploration of the antigen-processing machinery

Immunological Reviews

Volumn 207, Issue , 2005, Pages 60-76

  Groothuis, Tom A M ^a   Griekspoor, Alexander C ^a   Neijssen, Joost J ^a   Herberts, Carla A ^a   Neefjes, Jacques J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDASE; PROTEASOME; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRIPEPTIDYL PEPTIDASE II; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ALLELE; ANTIGEN PRESENTATION; CELL MEMBRANE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN TRANSPORT; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS;

EID: 26244461898     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00305.x     Document Type: Review

References (162)

1. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-779.
2. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
3. Turner GC, Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. Science 2000;289:2117-2120.
4. Lehner PJ, Trowsdale J. Antigen presentation: coming out gracefully. Curr Biol 1998;8:R605-R608.
5. Jackson PK, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000;10:429-439.
6. Haglund K, Di Fiore PP, Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 2003;28:598-603.
7. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999;96:635-644.
8. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005;120:73-84.
9. Reits EA, Benham AM, Plougastel B, Neefjes J, Trowsdale J. Dynamics of proteasome distribution in living cells. EMBO J 1997;16:6087-6094.
10. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 2004;1695:189-207.
11. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003;424:797-801.
12. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001;2:179-187.
13. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-847.
14. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 1995;268:579-582.
15. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995;268:533-539.
16. Hisamatsu H, et al. Newly identified pair of proteasomal subunits regulated reciprocally by Interferon gamma. J Exp Med 1996;183:1807-1816.
17. Beck S, Trowsdale J. Sequence organisation of the class II region of the human MHC. Immunol Rev 1999;167:201-210.
18. Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002;15:287-296.
19. Toes RE, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001;194:1-12.
20. Whitby FG, et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000;408:115-120.
21. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 1994;269:7709-7718.
22. Leggett DS, et al. Multiple associated proteins regulate proteasome structure and function. Mol Cell 2002;10:495-507.
23. Fu H, et al. Multiubiquitin chain binding and protein degradation are mediated by distinct domains within the 26 S proteasome subunit Mcb1. J Biol Chem 1998;273:1970-1981.
24. van Mocker S, et al. The multiubiquitin-chain-binding protein Mcb1 is a component of the 26S proteasome in Saccharomyces cerevisiae and plays a nonessential, substrate-specific role in protein turnover. Mol Cell Biol 1996;16:6020-6028.
25. Verma R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002;298:611-615.
26. Glickman MH, et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 1998;94:615-623.
27. Glickman MH, Rubin DM, Fried VA, Finley D. The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol Cell Biol 1998;18:3149-3162.
28. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 2002;296:548-550.
29. Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002;39:147-164.
30. Dick TP, et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 1996;86:253-262.
31. Preckel T, et al. Impaired immunoproteasome assembly and immune responses in PA28-/- mice. Science 1999;286:2162-2165.
32. Reits EA, Vos JC, Gromme M, Neefjes J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000;404:774-778.
33. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000;404:770-774.
34. Princiotta MF, et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003;18:343-354.
35. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 2003;3:952-961.
36. Kisselev AF, Akopian TN, Goldberg AL. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J Biol Chem 1998;273:1982-1989.
37. Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 2001;20:2357-2366.
38. Reits E, et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004;20:495-506.
39. Reits E, et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 2003;18:97-108.
40. Oliveira V, et al. Substrate specificity characterization of recombinant metallo oligopeptidases thimet oligopeptidase and neurolysin. Biochemistry 2001;40:4417-4425.
41. Saric T, Graef CI, Goldberg AL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 2004;279:46723-46732.
42. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-194.
43. Geier E, et al. A giant protease with potential to substitute for some functions of the proteasome. Science 1999;283:978-981.
44. Turzynski A, Mentlein R. Prolyl aminopeptidase from rat brain and kidney. Action on peptides and identification as leucyl aminopeptidase. Eur J Biochem 1990;190:509-515.
45. Beninga J, Rock KL, Goldberg AL. Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem 1998;273:18734-18742.
46. Bromme D, Rossi AB, Smeekens SP, Anderson DC, Payan DG. Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 1996;35:6706-6714.
47. Johnson GD, Hersh LB. Studies on the subsite specificity of the rat brain puromycin-sensitive aminopeptidase. Arch Biochem Biophys 1990;276:305-309.
48. Saric T, Beninga J, Graef CI, Akopian TN, Rock KL, Goldberg AL. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J Biol Chem 2001;276:36474-36481.
49. Stoltze L, et al. Two new proteases in the MHC class I processing pathway. Nat Immunol 2000;1:413-418.
50. Tomkinson B. Tripeptidyl peptidases: enzymes that count. Trends Biochem Sci 1999;24:355-359.
51. Herberts C, Reits E, Neefjes J. Proteases, proteases and proteases for presentation. Nat Immunol 2003;4:306-308.
52. Seifert U, et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol 2003;4:375-379.
53. Ray K, Hines CS, Coll-Rodriguez J, Rodgers DW. Crystal structure of human thimet oligopeptidase provides insight into substrate recognition, regulation, and localization. J Biol Chem 2004;279:20480-20489.
54. York IA, et al. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 2003;18:429-440.
55. Cresswell P, Bangia N, Dick T, Diedrich G. The nature of the MHC class I peptide loading complex. Immunol Rev 1999;172:21-28.
56. Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993;261:769-771.
57. Shepherd JC, et al. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993;74:577-584.
58. Reits EA, Griekspoor AC, Neefjes J. How does TAP pump peptides? Insights from DNA repair and traffic ATPases. Immunol Today 2000;21:598-600.
59. Bauer D, Tampe R. Herpes viral proteins blocking the transporter associated with antigen processing TAP - from genes to function and structure. Curr Top Microbiol Immunol 2002;269:87-99.
60. Arora S, Lapinski PE, Raghavan M. Use of chimeric proteins to investigate the role of transporter associated with antigen processing (TAP) structural domains in peptide binding and translocation. Proc Natl Acad Sci USA 2001;98:7241-7246.
61. Ahn K, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-621.
62. Hengel H, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-632.
63. Koppers-Lalic D, et al. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci USA 2005;102:5144-5149.
64. Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci USA 1997;94:6904-6909.
65. Nijenhuis M, Hammerling GJ. Multiple regions of the transporter associated with antigen processing (TAP) contribute to its peptide binding site. J Immunol 1996;157:5467-5477.
66. Vos JC, Reits EA, Wojcik-Jacobs E, Neefjes J. Head-head/tail-tail relative orientation of the pore-forming domains of the heterodimeric ABC transporter TAP. Curr Biol 2000;10:1-7.
67. Vos JC, Spec P, Momburg F, Neefjes J. Membrane topology and dimerization of the two subunits of the transporter associated with antigen processing reveal a three-domain structure. J Immunol 1999;163:6679-6685.
68. Koopmann JO, Post M, Neefjes JJ, Hammerling GJ, Momburg F. Translocation of long peptides by transporters associated with antigen processing (TAP). Eur J Immunol 1996;26:1720-1728.
69. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med 1994;180:1591-1597.
70. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med 1994;179:1613-1623.
71. Neefjes J, et al. Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur J Immunol 1995;25:1133-1136.
72. van Endert PM, et al. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995;182:1883-1895.
73. Gromme M, et al. The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur J Immunol 1997;27:898-904.
74. Momburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-651.
75. Schumacher TN, et al. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med 1994;179:533-540.
76. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-219.
77. Neisig A, et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. J Immunol 1995;154:1273-1279.
78. Serwold T, Gaw S, Shastri N. ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat Immunol 2001;2:644-651.
79. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002;419:480-483.
80. Andersen MH, et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 1999;163:3812-3818.
81. Haurum JS, et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999;190:145-150.
82. Dick TP, Bangia N, Peaper DR, Cresswell P. Disulfide bond isomerization and the assembly of MHC class I-peptide complexes. Immunity 2002;16:87-98.
83. Ortmann B, Androlewicz MJ, Cresswell P. MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding. Nature 1994;368:864-867.
84. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996;5:103-114.
85. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol 1996;156:3196-3206.
86. Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002;16:509-520.
87. Lindquist JA, Jensen ON, Mann M, Hammerling GJ. ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J 1998;17:2186-2195.
88. Gao B, et al. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 2002;16:99-109.
89. Momburg F, Tan P. Tapasin - the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol Immunol 2002;39:217-233.
90. Tan P, Kropshofer H, Mandelboim O, Bulbuc N, Hammerling GJ, Momburg F. Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol 2002;168:1950-1960.
91. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line. 220. Immunity 1998;8:221-231.
92. Garbi N, et al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 2000;1:234-238.
93. Saric T, et al. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 2002;3:1169-1176.
94. York IA, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 2002;3:1177-1184.
95. Spee P, Subjeck J, Neefjes J. Identification of novel peptide binding proteins in the endoplasmic reticulum: Erp72, Calnexin, Grp170. Biochemistry 1999;38:10559-10566.
96. Lammert E, et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 1997;27:923-927.
97. Lammert E, Stevanovic S, Brunner J, Rammensee HG, Schild H. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur J Immunol 1997;27:1685-1690.
98. Spec P, Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 1997;27:2441-2449.
99. Singh-Jasuja H, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-1974.
100. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-120.
101. Johnson AE, van Waes MA. The translocon: a dynamic gateway at the ER membrane. Annu Rev Cell Dev Biol 1999;15:799-842.
102. Koopmann JO, et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 2000;13:117-127.
103. Stockton JD, Merkert MC, Kellaris KV. A complex of chaperones and disulfide isomerases occludes the cytosolic face of the translocation protein Sec61 p and affects translocation of the prion protein. Biochemistry 2003;42:12821-12834.
104. Ahn K, et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J 1996;15:3247-3255.
105. Fruh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
106. Hill A, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-415.
107. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol 1999;162:5049-5052.
108. Machold RP, Wiertz EJ, Jones TR, Ploegh HL. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J Exp Med 1997;185:363-366.
109. Park B, et al. The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US) 2, US3, US6, and US11 gene products. J Immunol 2002;168:3464-3469.
110. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985;43:215-222.
111. Ackrill AM, Blair GE. Expression of hamster MHC class I antigens in transformed cells and tumours induced by human adenoviruses. Eur J Cancer Clin Oncol 1988;24:1745-1750.
112. Ackrill AM, Blair GE. Regulation of major histocompatibility class I gene expression at the level of transcription in highly oncogenic adenovirus transformed rat cells. Oncogene 1988;3:483-487.
113. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005;86:241-305.
114. Belz GT, Carbone FR, Heath WR. Cross-presentation of antigens by dendritic cells. Crit Rev Immunol 2002;22:439-448.
115. Gromme M, et al. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci USA 1999;96:10326-10331.
116. Schirmbeck R, Melber K, Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur J Immunol 1995;25:1063-1070.
117. Schirmbeck R, Reimann J. Peptide transporter-independent, stress protein-mediated endosomal processing of endogenous protein antigens for major histocompatibility complex class I presentation. Eur J Immunol 1994;24:1478-1486.
118. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for TAP-independent MHC class I cross-presentation in vivo. Immunity 2004;21:155-165.
119. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397-402.
120. Houde M, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003;425:402-406.
121. Gagnon E, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell 2002;110:119-131.
122. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004;5:678-684.
123. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol 2005;6:107-113.
124. Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for intercellular organelle transport. Science 2004;303:1007-1010.
125. Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005;434:83-88.
126. Wei CJ, Xu X, Lo CW. Connexins and cell signaling in development and disease. Annu Rev Cell Dev Biol 2004;20:811-838.
127. Oviedo-Orta E, Howard Evans W. Gap junctions and connexin-mediated communication in the immune system. Biochim Biophys Acta 2004;1662:102-112.
128. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001;11:294-297.
129. Neefjes JJ, Ploegh HL. Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol 1988;18:801-810.
130. Kuijpers KC, et al. HLA class I and II molecules present influenza virus antigens with different kinetics. Eur J Immunol 1992;22:2339-2345.
131. Neisig A, Melief CJ, Neefjes J. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol 1998;160:171-179.
132. Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771.
133. Benham AM, Gromme M, Neefjes J. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading. J Immunol 1998;161:83-89.
134. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992;356:443-446.
135. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998;8:1-10.
136. Solheim JC, Harris MR, Kindle CS, Hansen TH. Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. J Immunol 1997;158:2236-2241.
137. Christiansen FT, Hawkins BR, Dawkins RL. Immune function in ankylosing spondylitics and their relatives: influence of disease and HLA B27. Clin Exp Immunol 1978;33:270-275.
138. Price P, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999;167:257-274.
139. Allele frequencies in worldwide populations. Available at http:www.allelefrequencies.net.
140. Apostolopoulos V, Lazoura E. Noncanonical peptides in complex with MHC class I. Expert Rev Vaccines 2004;3:151-162.
141. Stevanovic S. Structural basis of immunogenicity. Transpl Immunol 2002;10:133-136.
142. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci USA 1997;94:7156-7161.
143. Cardozo C, Kohanski RA. Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the 'immunoproteasome'. J Biol Chem 1998;273:16764-16770.
144. Fehling HJ, et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994;265:1234-1237.
145. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998;392:618-622.
146. Princiotta MF, et al. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinalvinyl sulfone require enzymatically active proteasomes for continued survival. Proc Natl Acad Sci USA 2001;98:513-518.
147. Balow RM, Tomkinson B, Ragnarsson U, Zetterqvist O. Purification, substrate specificity, and classification of tripeptidyl peptidase II. J Biol Chem 1986;261:2409-2417.
148. Yellen-Shaw AJ, Wherry EJ, Dubois GC, Eisenlohr LC. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol 1997;158:3227-3234.
149. Dauch P, Vincent JP, Checler F. Molecular cloning and expression of rat brain endopeptidase 3.4.24.16. J Biol Chem 1995;270:27266-27271.
150. Urban RG, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994;91:1534-1538.
151. Heemels MT, Schumacher TN, Wonigeit K, Ploegh HL. Peptide translocation by variants of the transporter associated with antigen processing. Science 1993;262:2059-2063.
152. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhutter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 2003;171:1741-1749.
153. Schumacher TN, Kantesaria DV, Serreze DV, Roopenian DC, Ploegh HL. Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides. Proc Natl Acad Sci USA 1994;91:13004-13008.
154. Hattori A, et al. Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells. J Biochem (Tokyo) 2000;128:755-762.
155. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993;75:693-708.
156. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994;265:398-402.
157. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994;12:181-207.
158. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
159. A database of MHC ligands and peptide motifs (Version 1.0). Available at http: www.syfpeithi.de
160. Bhasin M, Raghava GP. Analysis and prediction of affinity of TAP binding peptides using cascade SVM. Protein Sci 2004;13:596-607.
161. Daniel S, et al. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol 1998;161:617-624.
162. Nussbaum AK, Kuttler C, Tenzer S, Schild H. Using the World Wide Web for predicting CTL epitopes. Curr Opin Immunol 2003;15:69-74.